SPOTLIGHT -
Stéphane Champiat, MD, PhD, Talks Benefits With and Next Steps for SOT101 and Pembrolizumab
Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.
Stéphane Champiat, MD, PhD, Reviews Results With IL-2/IL15 Superagonist SOT101 From AURELIO-03 Trial
Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.
